Divi's Laboratories has reported results for third quarter ended December 31, 2023 (Q3FY24).
The company has reported 15.48% rise in its net profit at Rs 358 crore for the third quarter ended December 31, 2023 as compared to Rs 310 crore for the same quarter in the previous year. Total income of the company increased by 5.26% at Rs 1902 crore for Q3FY24 as compared Rs 1807 crore for corresponding quarter of the previous year.
On consolidated basis, the company has reported 16.99% rise in net profit at Rs 358 crore for Q3FY24 as compared to Rs 306 crore for the same quarter in the previous year. Total income of the company increased by 7.08% at Rs 1950 crore for Q3FY24 as compared Rs 1821 crore for corresponding quarter of the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: